Our observations are in accordance with previous studies showing that interruption of PI3K/AKT signaling sensitizes tumor cells to sorafenib-induced apoptosis14 and with the fact that we consistently found high basal levels of p-AKT, CDK4/6, and cyclin D1 in cell lines with acquired resistance to sorafenib. This evidence concerns the gene AKT1 and neoplasm.